Optimal care for early RA patients: The challenge of translating scientific data into clinical practice

Rheumatology

Volumn 50, Issue 7, 2011, Pages 1194-1200

  Verschueren, Patrick ^a   Westhovens, René ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biologicals; Combinatietherapie Bij Reumato de Artritis; Early RA; Health policy; Treatment strategy

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG EFFICACY; EARLY DIAGNOSIS; EARLY INTERVENTION; HEALTH CARE PERSONNEL; HUMAN; LONG TERM CARE; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BELGIUM; BIOLOGICAL AGENTS; BIOMEDICAL RESEARCH; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; HEALTH PLAN IMPLEMENTATION; HUMANS; MALE; PATIENT CARE PLANNING; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79959463561     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker131     Document Type: Review

References (73)

1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
2. Walker D, Hall S. NICE guidance on rheumatoid arthritis: implications and challenges for rheumatologists. Rheumatology 2010;49:619-20.
3. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Management of rheumatoid arthritis: summary of NICE guidance. Br Med J 2009;338:b702.
4. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
5. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350: 309-18.
6. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
7. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
8. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
9. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
10. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, doubleblind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
11. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372: 375-82.
12. Westhovens R, Robles M, Ximenes AC et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
13. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15.
14. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology 2008;47:59-64.
15. Korthals-de Bos I, Van Tulder M, Boers M et al. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. J Rheumatol 2004;31:1709-16.
16. Esselens G, Westhovens R, Verschueren P. Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Musculoskeletal Care 2009;7:1-16.
17. van Tuyl LH, Plass AM, Lems WF et al. Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. Rheumatology 2008;47:1571-6.
18. van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Dijkmans BA, Boers M. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007;66:974-6.
19. Kiely P, Williams R, Walsh D, Young A. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. Rheumatology 2009;48:57-60.
20. Esselens GH, De Brabander A, Ovaere L, De Brabanter G, Moons P, Westhovens R. Personal attributes as determinants of timely care in rheumatoid arthritis. Ann Rheum Dis 2006;65:967-8.
21. Kumar K, Daley E, Carruthers DM et al. Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists. Rheumatology 2007;46:1438-40.
22. Sheppard J, Kumar K, Buckley CD, Shaw KL, Raza K. 'I just thought it was normal aches and pains': a qualitative study of decision-making processes in patients with early rheumatoid arthritis. Rheumatology 2008;47:1577-82.
23. Lard LR, Huizinga TW, Hazes JM, Vliet Vlieland TP. Delayed referral of female patients with rheumatoid arthritis. J Rheumatol 2001;28:2190-2.
24. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.
25. Gao IK, Haas-Wohrle A, Mueller KG, Lorenz HM, Fiehn C. Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist? Ann Rheum Dis 2005;64:1516-7.
26. Raza K, Breese M, Nightingale P et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005;32: 231-8.
27. Robinson PC, Taylor WJ. Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals. J Clin Rheumatol 2010;16:267-73.
28. Cush JJ. Early arthritis clinics: if you build it will they come? J Rheumatol 2005;32:203-7.
29. McGonagle D, Ash ZR, Hodgson RJ, Emery P, Radjenovic A. MRI for the assessment and monitoring of RA-what can it tell us? Nat Rev Rheumatol 2011;7: 185-9.
30. Brown AK. Using ultrasonography to facilitate best practice in diagnosis and management of RA. Nat Rev Rheumatol 2009;5:698-706.
31. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
32. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
33. Nishimura K, Sugiyama D, Kogata Y et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
34. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007;53: 498-504.
35. Skapenko A, Prots I, Schulze-Koops H. Prognostic factors in rheumatoid arthritis in the era of biologic agents. Nat Rev Rheumatol 2009;5:491-6.
36. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
37. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
38. Smolen JS, van der Heijde DM, St Clair EW et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
39. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56:1765-75.
40. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology 2009; 48:1114-21.
41. Durnez A, Vanderschueren G, Lateur L, Westhovens R, Verschueren P. Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Ann Rheum Dis 2011;70:634-7.
42. Visser K, Goekoop-Ruiterman YP, Vries-Bouwstra JK et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010;69:1333-7.
43. Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol 2009;38:166-72.
44. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35.
45. Verstappen SM, Albada-Kuipers GA, Bijlsma JW et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005;64:38-43.
46. Groarke A, Curtis R, Coughlan R, Gsel A. The role of perceived and actual disease status in adjustment to rheumatoid arthritis. Rheumatology 2004;43:1142-9.
47. Geuskens GA, Burdorf A, Evers AW, Hazes JM. Clear associations between demographic and psychosocial factors and health-related quality of life in patients with early inflammatory joint complaints. J Rheumatol 2008;35: 1754-61.
48. Scharloo M, Kaptein AA, Weinman J et al. Illness perceptions, coping and functioning in patients with rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis. J Psychosom Res 1998;44:573-85.
49. Hill J. Rheumatology nurse specialists-do we need them? Rheumatology 2007;46:379-81.
50. Fautrel B, Pham T, Gossec L et al. Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2005;72: 163-70.
51. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 2001;60: 869-75.
52. Abourazzak F, El Mansouri L, Huchet D et al. Long-term effects of therapeutic education for patients with rheumatoid arthritis. Joint Bone Spine 2009;76: 648-53.
53. Durez P, Malghem J, Nzeusseu Toukap A et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007; 56:3919-27.
54. Landewe RB, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
55. van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374: 459-66.
56. Soubrier M, Puechal X, Sibilia J et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 2009;48:1429-34.
57. van Tuyl LH, Boers M, Lems WF et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010;69:807-12.
58. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
59. van der Bijl AE, Goekoop-Ruiterman YP, Vries-Bouwstra JK et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007;56:2129-34.
60. van der Kooij SM, Goekoop-Ruiterman YP, Vries-Bouwstra JK et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009;68:914-21.
61. Aletaha D. Therapy: Challenging the course of RA: time for drug-free remission? Nat Rev Rheumatol 2010;6:442-3.
62. van der Woude D, Young A, Jayakumar K et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009;60:2262-71.
63. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
64. Verstappen SM, Jacobs JW, van der Veen MJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA). Ann Rheum Dis 2007;66:1443-9.
65. Keystone EC. Tight control for the management of RA-a therapeutic approach worth pursuing. Nat Clin Pract Rheumatol 2008;4:57.
66. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis 2007;66: 1227-32.
67. van der Goes MC, Jacobs JW, Boers M et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69: 1015-21.
68. Hoes JN, Jacobs JW, Boers M et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7.
69. van Tuyl LH, Plass AM, Lems WF et al. Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study. J Rheumatol 2009;36: 1380-6.
70. Verhoeven AC, Bibo JC, Boers M, Engel GL, Van Der LS. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoide Artritis. Br J Rheumatol 1998;37:1102-9.
71. Tijhuis GJ, Zwinderman AH, Hazes JM, van den Hout WB, Breedveld FC, Vliet Vlieland TP. A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis. Arthritis Rheum 2002;47:525-31.
72. van den Hout WB, Tijhuis GJ, Hazes JM, Breedveld FC, Vliet Vlieland TP. Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: a randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Ann Rheum Dis 2003;62:308-15.
73. Benhamou M, Rincheval N, Roy C et al. The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol 2009;36: 934-42.